These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33035554)

  • 1. EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma.
    Liu X; He J; Mao L; Zhang Y; Cui W; Duan S; Jiang A; Gao Y; Sang Y; Huang G
    Exp Eye Res; 2021 Jan; 202():108286. PubMed ID: 33035554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
    Chan-Penebre E; Kuplast KG; Majer CR; Boriack-Sjodin PA; Wigle TJ; Johnston LD; Rioux N; Munchhof MJ; Jin L; Jacques SL; West KA; Lingaraj T; Stickland K; Ribich SA; Raimondi A; Scott MP; Waters NJ; Pollock RM; Smith JJ; Barbash O; Pappalardi M; Ho TF; Nurse K; Oza KP; Gallagher KT; Kruger R; Moyer MP; Copeland RA; Chesworth R; Duncan KW
    Nat Chem Biol; 2015 Jun; 11(6):432-7. PubMed ID: 25915199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
    Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
    BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
    Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
    Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JQ1, a selective inhibitor of BRD4, suppresses retinoblastoma cell growth by inducing cell cycle arrest and apoptosis.
    Zhang Y; Duan S; Jang A; Mao L; Liu X; Huang G
    Exp Eye Res; 2021 Jan; 202():108304. PubMed ID: 33080301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.
    Gullà A; Hideshima T; Bianchi G; Fulciniti M; Kemal Samur M; Qi J; Tai YT; Harada T; Morelli E; Amodio N; Carrasco R; Tagliaferri P; Munshi NC; Tassone P; Anderson KC
    Leukemia; 2018 Apr; 32(4):996-1002. PubMed ID: 29158558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of protein arginine methyltransferase 5 in inflammation and migration of fibroblast-like synoviocytes in rheumatoid arthritis.
    Chen D; Zeng S; Huang M; Xu H; Liang L; Yang X
    J Cell Mol Med; 2017 Apr; 21(4):781-790. PubMed ID: 27860244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor.
    Rioux N; Duncan KW; Lantz RJ; Miao X; Chan-Penebre E; Moyer MP; Munchhof MJ; Copeland RA; Chesworth R; Waters NJ
    Xenobiotica; 2016; 46(3):268-77. PubMed ID: 26294260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
    Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
    J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective PRMT5 Inhibitors Suppress Human CD8
    Strobl CD; Schaffer S; Haug T; Völkl S; Peter K; Singer K; Böttcher M; Mougiakakos D; Mackensen A; Aigner M
    Mol Cancer Ther; 2020 Feb; 19(2):409-419. PubMed ID: 31712395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5.
    Zhang B; Zhang S; Zhu L; Chen X; Zhao Y; Chao L; Zhou J; Wang X; Zhang X; Ma N
    Toxicol Appl Pharmacol; 2017 Dec; 336():1-7. PubMed ID: 28987382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xanthatin Selectively Targets Retinoblastoma by Inhibiting the PLK1-Mediated Cell Cycle.
    Yang J; Li Y; Zong C; Zhang Q; Ge S; Ma L; Fan J; Zhang J; Jia R
    Invest Ophthalmol Vis Sci; 2021 Dec; 62(15):11. PubMed ID: 34901994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
    Zhu K; Song JL; Tao HR; Cheng ZQ; Jiang CS; Zhang H
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3693-3699. PubMed ID: 30366617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRMT5 promotes retinoblastoma development.
    Jiang Y; Zheng G; Sun X
    Hum Cell; 2023 Jan; 36(1):329-341. PubMed ID: 36331723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
    Prabhu L; Chen L; Wei H; Demir Ö; Safa A; Zeng L; Amaro RE; O'Neil BH; Zhang ZY; Lu T
    Mol Biosyst; 2017 Nov; 13(12):2509-2520. PubMed ID: 29099132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of PRMT5 suppresses osteoclast differentiation and partially protects against ovariectomy-induced bone loss through downregulation of CXCL10 and RSAD2.
    Dong Y; Song C; Wang Y; Lei Z; Xu F; Guan H; Chen A; Li F
    Cell Signal; 2017 Jun; 34():55-65. PubMed ID: 28302565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
    Chung J; Karkhanis V; Tae S; Yan F; Smith P; Ayers LW; Agostinelli C; Pileri S; Denis GV; Baiocchi RA; Sif S
    J Biol Chem; 2013 Dec; 288(49):35534-47. PubMed ID: 24189068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.
    Zhang B; Dong S; Li Z; Lu L; Zhang S; Chen X; Cen X; Wu Y
    J Transl Med; 2015 Nov; 13():349. PubMed ID: 26541651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.
    Jiang Y; Yuan Y; Chen M; Li S; Bai J; Zhang Y; Sun Y; Wang G; Xu H; Wang Z; Zheng Y; Nie H
    Theranostics; 2021; 11(18):9162-9176. PubMed ID: 34522232
    [No Abstract]   [Full Text] [Related]  

  • 20. MicroRNA-129-5p suppresses proliferation, migration and invasion of retinoblastoma cells through PI3K/AKT signaling pathway by targeting PAX6.
    Liu Y; Liang G; Wang H; Liu Z
    Pathol Res Pract; 2019 Dec; 215(12):152641. PubMed ID: 31727502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.